Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY


Business Summary
Logo Eli Lilly and Company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Number of employees : 33 625 people.
Sales per Business
USD (in Million)%
Pharmaceutical Products22,320100%
Sales per region
USD (in Million)%USD (in Million)%
United States13,87556.5%12,72357% -8.31%
Europe4,23117.2%3,76516.9% -11.02%
Other Foreign Countries3,95616.1%3,28414.7% -16.97%
Japan2,49410.2%2,54811.4% +2.16%
Managers and Directors
David Ricks522017Chairman, President & Chief Executive Officer
Joshua L. Smiley502018Chief Financial Officer & Senior Vice President
Timothy J. Garnett, Dr.-1998Chief Medical Officer & VP-Global Medical
Aarti S. Shah, Dr.56-Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky, Dr.47-Chief Scientific Officer & Senior Vice President
Kathi P. Seifert711995Independent Director
Jon Erik Fyrwald612005Independent Director
Michael L. Eskew702008Independent Director
Ralph Alvarez642009Independent Director
Katherine Baicker, Dr.482011Independent Director
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 957,068,598 955,049,005 99.8% 487,000 0.1% 99.8%
Lilly Endowment, Inc. 110,702,343 11.6%
Capital Research & Management Co. 109,033,091 11.4%
The Vanguard Group, Inc. 65,354,284 6.83%
The PNC Financial Services Group, Inc. 50,000,000 5.23%
PRIMECAP Management Co. 37,975,324 3.97%
SSgA Funds Management, Inc. 34,935,118 3.65%
Fidelity Management & Research Co. LLC 28,083,352 2.94%
Wellington Management Co. LLP 25,317,842 2.65%
BlackRock Fund Advisors 19,675,191 2.06%
State Farm Investment Management Corp. 18,619,725 1.95%
Sigilon Therapeutics, Inc. (SGTX) 2,744,4439.09%131,815,597 USD
Dicerna Pharmaceuticals, Inc. (DRNA) 5,414,1857.21%119,274,496 USD
Avidity Biosciences, Inc. (RNA) 2,169,3965.78%55,362,986 USD
Precision BioSciences, Inc. (DTIL) 3,762,1907.17%31,376,665 USD
NextCure, Inc. (NXTC) 2,088,8597.58%22,768,563 USD
AC Immune SA (ACIU) 00.0000%
Company contact information
Eli Lilly & Co.
Lilly Corporate Center
Indianapolis, IN 46285

Phone : +1.317.276.2000
Web : http://www.lilly.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Eli Lilly and Company
Sector Pharmaceuticals - NEC